Literature DB >> 25583216

Using DTA and DTAARRAY variables and programming in WinNonlin ASCII models to streamline user-defined calculation and data analysis.

Jun Shen1, Shuanglian Li, Ronald R Bowsher, Andrew Vick.   

Abstract

In pharmacokinetic (PK) analysis, there are many occasions where user-defined calculations need to be performed before or after the primary PK modeling/analysis. Conventionally, these calculations are often executed outside of the primary PK analysis by pre- or post-processing data from multiple sources, manually entering formulas and multiple additional set-ups. Such analysis approaches increase the risk of generating data defects and can employ software that is not fully compliant. We propose a method of leveraging DTA and DTAARRAY variables plus simple programming techniques in an ASCII model to automate these user-defined calculations in WinNonlin and eliminate the need for manual handling of data outside of the primary analysis. We demonstrated the application of this strategy through three case study examples. In case 1 (post-processing data), DTA variables were used to calculate three user-defined parameters in the primary PK model. In case 2 (pre-processing data), a baseline correction decision tree was programmed into the PK model to account for both the endogenous baseline level as well as the presence of residual drug. In case 3, DTAARRAY variables were used to perform a looping operation to calculate the difference factor (F1) and the similarity factor (F2) in support of in vitro bioequivalence evaluations.

Entities:  

Mesh:

Year:  2015        PMID: 25583216      PMCID: PMC4365079          DOI: 10.1208/s12248-014-9711-7

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  4 in total

1.  B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study.

Authors:  C M Kessler; J C Gill; G C White; A Shapiro; S Arkin; D A Roth; X Meng; J M Lusher
Journal:  Haemophilia       Date:  2005-03       Impact factor: 4.287

2.  In vitro dissolution profile comparison--statistics and analysis of the similarity factor, f2.

Authors:  V P Shah; Y Tsong; P Sathe; J P Liu
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

3.  Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

Authors:  Amy D Shapiro; Margaret V Ragni; Leonard A Valentino; Nigel S Key; Neil C Josephson; Jerry S Powell; Gregory Cheng; Arthur R Thompson; Jaya Goyal; Karen L Tubridy; Robert T Peters; Jennifer A Dumont; Donald Euwart; Lian Li; Bengt Hallén; Peter Gozzi; Alan J Bitonti; Haiyan Jiang; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2011-11-22       Impact factor: 22.113

4.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Authors:  Jerry S Powell; Neil C Josephson; Doris Quon; Margaret V Ragni; Gregory Cheng; Ella Li; Haiyan Jiang; Lian Li; Jennifer A Dumont; Jaya Goyal; Xin Zhang; Jurg Sommer; Justin McCue; Margaret Barbetti; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

  4 in total
  2 in total

1.  Propofol target-controlled infusion modeling in rabbits: Pharmacokinetic and pharmacodynamic analysis.

Authors:  Jian-Yan Chen; Ming Yi; Shang-Long Yao; Xue-Ping Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-05

2.  A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.

Authors:  James S McCarthy; Thomas Rückle; Elhadj Djeriou; Cathy Cantalloube; Daniel Ter-Minassian; Mark Baker; Peter O'Rourke; Paul Griffin; Louise Marquart; Rob Hooft van Huijsduijnen; Jörg J Möhrle
Journal:  Malar J       Date:  2016-09-13       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.